The application of heat represents a useful tool to optimize the production of challenging synthetic peptides, and a new technology, induction heating, has been introduced on the Prelude X.
New and optimized methods for rapid peptide synthesis, combined with instruments capable of parallel synthesis enable the production of peptide libraries with high throughput.
Building upon the strength of the original Prelude platform, the Prelude X adds heating, oscillation shaking, and UV monitoring to deliver uncompromised speed, yield, reagent savings, and flexibility, creating the most complete peptide synthesis solution available.
Heat-assisted synthesis has been shown to reduce the time necessary to produce high-purity linear peptides, and its application to the synthesis of cyclic peptides may provide similar advantages.
The Symphony X™ multiple peptide synthesizer offers the most flexibility and independent protocols of any instrument on the market, making it an ideal platform for high-throughput process development.
Peptides have been recognized as highly selective and generally well tolerated drug candidates, increasing the demand for rapid access to different peptide sequences in order to accelerate the evaluation of potential therapeutics.
The coupling reagent COMU has been demonstrated to be highly efficient in the synthesis of a variety of peptides.
Human parathyroid hormone (1-84) (PTH) (Figure 1) is produced by the parathyroid glands and regulates calcium and phosphate metabolism. PTH acts on PTHR1 receptors to stimulate bone formation and is used as a treatment for osteoporosis and hypoparathyroidism, a rare deficiency of parathyroid hormone [1,2]
Peptide based drug discovery and research is increasingly at the forefront in addressing new therapeutic challenges due to their high target selectivity and potency with low toxicity. Automated solid phase peptide synthesis (SPPS) increases reliability, efficiency and crude purity for peptides in drug discovery and development.
Type-II diabetes, caused by chronic insulin resistance and a progressive decline in pancreatic -cell function, affects over 150 million people worldwide . The 37-mer human islet amyloid polypeptide (IAPP) (Figure 1) or amylin, is a major contributor to the amyloid deposits found in the pancreases of patients with typeII diabetes [2,3].
Human β-amyloid (1-42) (Figure 1) is a major component of the plaque deposits found in the brains of patients with Alzheimer’s disease (AD) . b-amyloid is in constant demand for the continued research into the pathology, diagnostic tools, and potential therapeutics for AD.